Top
image credit: Adobe Stock

Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies

November 30, 2022

The company also announced dosing of the first patient in its Phase 1 clinical trial of NTX1088, Nectin’s first-in-class PVR blocker, in cancer patients with locally advanced and metastatic solid tumors. NTX1088 is a first-in-class high affinity monoclonal antibody directed against PVR (CD155), a transmembrane protein expressed on cancer cells and associated with resistance to PD1 and PDL1 immune checkpoint inhibitors. The trial is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) with an investment from the Cancer Focus Fund, LP. The trial will include up to 90 patients treated with NTX1088 as a monotherapy and in combination with a PD1 blocker.

Read More on HitConsultant